



Unusual Calls Bought in Quotient

Ticker/Price: QTNT (\$8.8)

Analysis:

Quotient (QTNT) with 1000 April \$7.50 calls bought today \$2.35 to \$2.40, spot where 1000 accumulated in OI earlier this month and these likely to add. QTNT shares look to be basing above the \$8 mark, also being two year trend support and strength today up 3.15%. The \$535M commercial-stage diagnostics Co. based in Switzerland is trading 21X EV/Sales, a name that posted 20%, 11% and 17.8% revenue growth the last three years and in 2020 sees a pick-up in growth starting in 2H. QTNT is coming off a beat and raise quarter. In February 2018 two Directors bought around \$100K worth of stock \$3.87 to \$4.28. QTNT is seen to be a transformative play on transfusion diagnostics, a \$3.4B market separated into Donor and Patient Testing. There are some big players in the group like Beckman Coulter, GRFS, BIO, ABT, and Roche. QTNT's product offers a value proposition and has the highest throughput and productivity. It has a vast pipeline coming into market the next few years. Analysts have an average target of \$13.50 on shares and short interest is 21% of the float. The name has not seen much Analyst coverage while Q2 hedge fund ownership rose 9.7%. Perceptive Advisors has a large \$100M position.

Hawk Vision:



Hawk's Perspective: QTNT is an intriguing small cap diagnostics play and want to first confirm OI change tomorrow while have alert set at \$9.50.

Confidence Ranking: \$\$